About the Authors
- Preeti H. Negandhi
-
Contributed equally to this work with: Preeti H. Negandhi, Nazim Ghouri
Affiliation Indian Institute of Public Health, Public Health Foundation of India, Gurgaon, Haryana, India
- Nazim Ghouri
-
Contributed equally to this work with: Preeti H. Negandhi, Nazim Ghouri
* E-mail: nazim.ghouri@glasgow.ac.uk
Affiliation Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom
- Helen M. Colhoun
-
Affiliation Biomedical Research Institute, Mackenzie Building, University of Dundee, Dundee, Scotland, United Kingdom
- Colin M. Fischbacher
-
Affiliation Information Services Division, NHS National Services Scotland, Edinburgh, Scotland, United Kingdom
- Robert S. Lindsay
-
Affiliation Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom
- John A. McKnight
-
Affiliation Metabolic Unit, Western General Hospital, Edinburgh, Scotland, United Kingdom
- John Petrie
-
Affiliation Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom
- Sam Philip
-
Affiliation Department of Diabetes and Endocrinology, Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom
- Naveed Sattar
-
Affiliation Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom
- Sarah H. Wild
-
Affiliation Centre for Population Health Sciences, University of Edinburgh, Medical School, Edinburgh, Scotland, United Kingdom
- on behalf of the Scottish Diabetes Research Network Epidemiology Group
Competing Interests
HMC received monies from Pfizer for attending symposia, a speaker's bureau, as a member of staff and for consultancy. HMC has received research funds from Pfizer, Roche, Eli-Lilly, Boehringer Ingelheim (BI) and Astra Zeneca. HMC has shares in Roche. JAM is the PI for drug studies for Novo Nordisk, Eli Lilly and BI (contracts relating to this work are through JAM's NHS employer R&D department). JAM received monies 2 years ago from BI for organising the ethics application for their study and attending the meeting relating to this. JAM has received support to attend meetings from the above companies as well as from Takeda. This does not alter the authors' adherence to all PLOS ONE policies on sharing materials.
Author Contributions
Conceived and designed the experiments: SHW PHN. Performed the experiments: SHW PHN. Analyzed the data: PHN SHW. Wrote the paper: PHN NG NS SHW. Revised the manuscript critically for important intellectual content: PHN NG NS SHW HMC CMF RSL JAM JP SP.